Public Company News

Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA

SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the National Medical Products Administration (NMPA) inChina to ini...

2025-10-14 20:00 959

Sae-A Trading Achieves South Korea's First Better Cotton Initiative Physical Chain of Custody Certification

SEOUL, South Korea, Oct. 14, 2025 /PRNewswire/ -- Sae-A Trading, global apparel manufacturer and exporter, announced that it has become the first company in South Korea's textile and apparel industry to achieve certification under the Better Cotton Initiative (BCI) Physical Chain of Custody (CoC)...

2025-10-14 20:00 1027

Morgan Stanley Raises JOYY (JOYY.US) Target Price from US$40 to US$62 on Signs of Live Streaming Recovery and Attractive Shareholder Returns

SINGAPORE, Oct. 14, 2025 /PRNewswire/ -- Morgan Stanley has raised its target price for JOYY (JOYY.US) toUS$62 from US$40, reflecting improving fundamentals in JOYY's core business, accelerating advertising growth, and attractive shareholder returns. The firm also highlighted JOYY's robust cash p...

2025-10-14 19:16 1533

Iridium and Qualcomm Join Forces to Enable Satellite Connectivity in Snapdragon Mission Tactical Radio

Multiple Iridium data services integrated into the powerful Snapdragon platform for U.S. government and allied users MCLEAN, Va., Oct. 14, 2025 /PRNewswire/ -- Iridium Communications Inc.

2025-10-14 19:01 1007

Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults

-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection-- -- Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fol...

2025-10-14 18:18 1174

CNFinance Holdings Limited Regains Compliance with NYSE ADS Trading Price Requirement

GUANGZHOU, China, Oct. 14, 2025 /PRNewswire/ -- CNFinance Holdings Limited (NYSE: CNF) ("CNFinance" or the "Company"), a leading home equity loan service provider inChina, today announced that it has regained compliance with the New York Stock Exchange ("NYSE") continued listing standard for mini...

2025-10-14 18:05 1323

'NBA Cares x Sands Cares Community Impact Week' a Success

Five days of community engagement unites over 2,200 volunteers and community members NBA stars join forces to spread compassion through basketball MACAO, Oct. 14, 2025 /PRNewswire/ -- The final showdown of The NBA China Games 2025 took the court Sunday at The Venetian Arena. Alongside the games,...

2025-10-14 18:04 1451

Infosys Chosen by NHSBSA to Deliver a New Workforce Management Solution for the NHS in England and Wales

Next-Generation solution supports the NHS 10-year Health Plan and the mission to create a workforce that is fit for the future LONDON and BENGALURU, India, Oct. 14, 2025 /PRNewswire/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation di...

2025-10-14 18:02 1004

Solidion Technology Will Avoid Substantially Dilutive Share Sales

Company Intends to Shun Highly Toxic Financing Structures and May Consider Long-Term or Strategic Partners For Future Capital Needs DALLAS, Oct. 14, 2025 /PRNewswire/ -- Solidion Technology Inc. ("Solidion" or the "Company") (Nasdaq: STI), an advanced battery technology solutions provider, today...

2025-10-14 18:00 1240

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG, Oct. 14, 2025...

2025-10-14 18:00 1292

Tencent Music Entertainment Group to Report Third Quarter 2025 Financial Results on November 12, 2025

SHENZHEN, China, Oct. 14, 2025 /PRNewswire/ -- Tencent Music Entertainment Group ("TME", or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced that it will report its unaudited financial results for the third quarter of 2...

2025-10-14 18:00 1426

Invitation to presentation of Electrolux Group Q3 report

STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- On 30th of October, Electrolux Group will publish the results for the third quarter of 2025, at approx. 07.00 CET. Media, investors and analysts are invited to a simultaneous video webcast and telephone conference on the same day following the release of t...

2025-10-14 17:51 719

The Basque Government and IBM inaugurate Europe's first IBM Quantum System Two in Donostia-San Sebastián

* The IBM-Euskadi Quantum Computational Center now offers its members access to one of the most powerful quantum computers in the world. * The IBM-BasQ partnership will foster global scientific collaborations in fundamental physics and materials science. SAN SEBASTÍAN, Spain, Oct. 14, 2025 /P...

2025-10-14 17:41 900

IFS Loops Accelerates Industrial Operations with Agentic AI Digital Workers: Deployable Today, Scalable for Tomorrow

10 Digital Workers ready equipped with 50 agentic skills now, 100+ skills available by December LONDON, Oct. 14, 2025 /PRNewswire/ -- IFS, the leading provider of Industrial AI software, today announced the next evolution of its IFS Loops agent platform: 10 Digital Workers with 50 agentic skills...

2025-10-14 17:27 981

Truecaller crosses 450 Million active users on Android globally

STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- Truecaller, the leading global communication platform and Caller ID and spam-blocking service, today announced that it has surpassed 450 million monthly active users (MAUs) on Android. This is equivalent to approximately 10% of the global Android smartphon...

2025-10-14 17:11 834

TAL Education Group to Announce Second Quarter of Fiscal Year 2026 Financial Results on October 30, 2025

BEIJING, Oct. 14, 2025 /PRNewswire/ -- TAL Education Group ("TAL" or the "Company") (NYSE: TAL), a smart learning solutions provider inChina, today announced that it will release its unaudited financial results for the second quarter of fiscal year 2026 endedAugust 31, 2025, before the market ope...

2025-10-14 17:00 1320

COMFORT IS THE NEW LUXURY: MARRIOTT INTERNATIONAL UNVEILS ASIA PACIFIC'S CULINARY FUTURE

Marriott International's Future of Food 2026 reveals how a shift towards comfort-driven luxury and experiences rooted in local culinary traditions are redefining a new era of indulgence SINGAPORE, Oct. 14, 2025 /PRNewswire/ -- Marriott International has unveiled its latest report, The Future of ...

2025-10-14 16:00 1347

NEW RESEARCH: Kemira Water Index 2025 exposes critical weaknesses in water resilience and alarming consumer unpreparedness

New international study led by Kemira identifies where people are most vulnerable if their community suddenly loses access to clean water due to extreme weather-related disasters, outdated infrastructure and toxic contaminants * 91% of people surveyed across Europe and the US are concerned abo...

2025-10-14 15:00 1020

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended30 September 2025 (Q3 2025). All figures are in USD unless stated otherwi...

2025-10-14 14:59 1406

Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting

TAIPEI, Oct. 14, 2025 /PRNewswire/ -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor for cancer immunotherapy. GNTbm-TKI will be presented as posters at the 2025European Society for Medical Oncology (ESMO) Annual Meet...

2025-10-14 14:26 914
1 ... 66676869707172 ... 1667

Week's Top Stories